Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept in Renal Transplant with Mild Immunologic Risk
NCT02738918Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Dec 2014
- Primary completion
- Sep 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of belatacept in renal transplant rejection (RTR), acute antibody-mediated rejection (AMR), sponsored by Assistance publique - Hôpitaux de Paris. Started Dec 2014; status: completed.
02
Drugs
belatacept
03
Conditions
renal transplant rejection (RTR)acute antibody-mediated rejection (AMR)
Beyond the preview
Go deeper on NCT02738918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02738918.